Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI +0.21%63 Return-on-Tangible-Asset is 0.81% as of Mar. 2026, which is 95% below its 10-year median of 17.44. GuruFocus rates NSE:BALAXI with a GF Score™ of 63/100 and a GF Value™ of ₹69.23 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks worse than 61.9% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Balaxi Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹25 Mil. Balaxi Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was ₹3,044 Mil. Therefore, Balaxi Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.81%.
The historical rank and industry rank for Balaxi Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
NSE:BALAXI'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -37.96 Med: 17.44 Max: 56.76
Current: 0.48
During the past 12 years, Balaxi Pharmaceuticals's highest Return-on-Tangible-Asset was 56.76%. The lowest was -37.96%. And the median was 17.44%.
NSE:BALAXI's Return-on-Tangible-Asset is ranked worse than 61.9% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.12
vs NSE:BALAXI: 0.48
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Balaxi Pharmaceuticals Return-on-Tangible-Asset Related Terms
Balaxi Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Balaxi Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BALAXI vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.81% mean?
Balaxi Pharmaceuticals (NSE:BALAXI) has a Return-on-Tangible-Asset of 0.81% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Balaxi Pharmaceuticals and its competitors. This is 95% below median its historical median of 17.44. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #624 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 61.9%.
Is Balaxi Pharmaceuticals' Return-on-Tangible-Asset too high?
Balaxi Pharmaceuticals' current Return-on-Tangible-Asset of 0.81% is 95% below median its 10-year median of 17.44. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.12. Balaxi Pharmaceuticals' value of 0.81% is 74% below this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #624 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Balaxi Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #624 out of 1008 companies for Return-on-Tangible-Asset. This places Balaxi Pharmaceuticals in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.12. Balaxi Pharmaceuticals' value of 0.81% is 74% below this benchmark. While the company's 10-year median is 17.44 vs. the industry median of 3.12, Balaxi Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.12, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current Return-on-Tangible-Asset of 0.81% is 74% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current Return-on-Tangible-Asset is 0.81%, which is 95% below median its own 10-year median of 17.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.23, compared to a current price of ₹24.44 — trading 64.7% below its estimated fair value. The current Return-on-Tangible-Asset is 0.81%, which is 95% below median its 10-year median of 17.44 and 74% below the Drug Manufacturers industry median of 3.12. Balaxi Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Return-on-Tangible-Asset is 0.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.44 is trading 64.7% below its estimated GF Value™ of ₹69.23.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
Return-on-Tangible-Asset: 0.81% (95% below median its 10-year median of 17.44)
GF Value™: ₹69.23 vs. price of ₹24.44 (64.7% below fair value)
Industry Position: 74% below the Drug Manufacturers median (#624 of 1008)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
63GF Score
Get the complete analysis for NSE:BALAXI
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
